[HTML][HTML] Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang, G Yang… - Heliyon, 2023 - cell.com
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang, G Yang… - Heliyon, 2023 - europepmc.org
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
[HTML][HTML] Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang, G Yang… - Heliyon - cell.com
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
[HTML][HTML] Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang, G Yang… - Heliyon, 2023 - ncbi.nlm.nih.gov
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
[HTML][HTML] Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang, G Yang… - Heliyon, 2023 - Elsevier
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
M He, D Zhang, Y Cao, C Chi, Z Zeng, X Yang… - …, 2023 - ui.adsabs.harvard.edu
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …